BioCentury
ARTICLE | Company News

ChronTech, Transgene deal

November 5, 2012 8:00 AM UTC

ChronTech said in its interim report for the nine months ending Sept. 30 that a collaboration with Transgene had been terminated. The companies partnered in April 2011 to conduct a Phase I trial to evaluate ChronTech's ChronVac-C plasmid DNA vaccine as a prime and Transgene's TG4040 vaccine as a boost to treat HCV genotype 1 infection. The companies could not be reached for details (see BioCentury, April 25, 2011). ...